Fibromyalgia, a chronic and multifaceted pain disorder, affects millions worldwide, presenting significant challenges in diagnosis, management, and treatment development.

Characterized by widespread musculoskeletal pain, fatigue, cognitive impairments, and sleep disturbances, fibromyalgia has long been recognized as a central nervous system disorder. Despite advancements in understanding its pathophysiology, including the roles of central sensitization and neurotransmitter imbalances, its precise etiology remains elusive.

This whitepaper explores the latest developments in fibromyalgia research, emphasizing diagnostic criteria, prevalence, and therapeutic advancements. It highlights critical unmet needs, including effective treatment strategies and equitable access to care, while offering a comprehensive overview of clinical trial outcomes, safety considerations, and market trends.

At iNGENū, we are dedicated to advancing the understanding and treatment of Fibromyalgia. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted by this challenging condition.